CDMO Perspective on Clinical Supply Planning for Studies with Unconventional Timelines
Summary: There is a growing need to help sponsors of clinical study drugs save time, reduce costs, and quickly get their products to market without compromising safety. To do this, sponsors might have the option to conduct studies that do not conform to the standard Phase 1 through Phase 3 clinical timeline, depending on the drug being researched. What kinds of trials can be managed in this manner, and how can unconventional timelines help sponsors achieve these specific time and cost goals?